One day before comments closed on the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights, published by the National Institute of Standards & Technology (NIST) and the Department of Commerce last month, the Department of Health and Human Services (HHS) denied an appeal of a decision not to march in on the blockbuster prostate cancer drug, Xtandi®.
Recent Posts
- Other Barks and Bites for Friday, May 10: Bipartisan Congress Members Call for GAO Study on March-In Proposal; USPTO Warns Trademark Applicants of Data Leak; Supreme Court Rejects Time Limit on Copyright Damages
- The World’s AI Companies Are Killing Trust in the Technology
- SCOTUS Rejects Three-Year Limit on Copyright Damages But Sidesteps Accrual Question
- G+ Communications v. Samsung: The Perils of Being ‘Half-Committed’ to FRAND
- Four Factors to Consider When Deciding Whether to Use Trade Secrets